Dr Robert Rifkin speaks to ecancer about managing multiple myeloma during the COVID-19 outbreak.
He begins by describing the US MM-6 study and how its approach is ideally suited to the current situation, due to use of oral regimens and the small number of visits to the clinic required.
Dr Rifkin explains that initially newly diagnosed patients will still need full lab tests, appropriate imaging and a bone marrow biopsy in order to be given the best care.
He details the important role telemedicine is playing in monitoring multiple myeloma patients and decreasing risk, with a third or more visits now over Zoom/Skype.
Prof Rifkin also discusses current research into treating COVID-19, covering the study of the potential use of BCL-2 inhibitors and also tocilizumab.
This programme has been supported by an unrestricted educational grant from Takeda.